News & Events

Press Releases

Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Lupus Nephritis

Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis

Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer

Kyverna Therapeutics Names Georg Schett, M.D., and Peter A. Merkel, M.D., MPH, to Scientific Advisory Board

Kyverna Therapeutics Names Cell Therapy Expert Tom Van Blarcom, Ph.D., as Senior Vice President, Head of Research

Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures

Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases

Kyverna Therapeutics Announces Exclusive Worldwide Licenses With National Institutes of Health for Autologous and Allogeneic Anti-CD19 CAR T Cellular Therapies to Treat Autoimmune Diseases

Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board and Karen Walker as Chief Technology Officer

Kyverna Therapeutics Announces the Appointment of James Chung, M.D., Ph.D., as Chief Medical Officer

Media Inquiries

To learn more about Kyverna’s work developing cell therapies for inflammatory and autoimmune disease, please reach out to us at:

media@kyvernatx.com